Free Trial
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

Prothena logo
$9.91 -0.01 (-0.13%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Prothena Stock (NASDAQ:PRTA)

Advanced

Key Stats

Today's Range
$9.85
$10.09
50-Day Range
$6.81
$9.99
52-Week Range
$4.32
$18.88
Volume
91,974 shs
Average Volume
1.03 million shs
Market Capitalization
$533.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.75
Consensus Rating
Hold

Company Overview

Prothena Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

PRTA MarketRank™: 

Prothena scored higher than 61% of companies evaluated by MarketBeat, and ranked 410th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prothena has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Upside Potential

    Prothena has a consensus price target of $19.75, representing about 97.1% upside from its current price of $10.02.

  • Amount of Analyst Coverage

    Prothena has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Prothena's stock forecast and price target.
  • Earnings Growth

    Earnings for Prothena are expected to grow in the coming year, from ($4.04) to ($3.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prothena is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prothena is -1.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prothena has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Prothena's valuation and earnings.
  • Percentage of Shares Shorted

    8.65% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently decreased by 7.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Prothena does not currently pay a dividend.

  • Dividend Growth

    Prothena does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.65% of the float of Prothena has been sold short.
  • Short Interest Ratio / Days to Cover

    Prothena has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prothena has recently decreased by 7.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Prothena has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Prothena this week, compared to 4 articles on an average week.
  • Search Interest

    Only 4 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Prothena insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Prothena is held by insiders.

  • Percentage Held by Institutions

    97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prothena's insider trading history.
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRTA Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Citizens JMP Remains a Buy on Prothena (PRTA)
See More Headlines

PRTA Stock Analysis - Frequently Asked Questions

Prothena's stock was trading at $13.85 at the start of the year. Since then, PRTA shares have decreased by 27.7% and is now trading at $10.0180.

Prothena Corporation plc (NASDAQ:PRTA) announced its quarterly earnings results on Monday, August, 4th. The biotechnology company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.11) by $0.75. The biotechnology company had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative trailing twelve-month return on equity of 62.17%.

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/04/2025
Today
10/06/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRTA
CIK
1559053
Employees
130
Year Founded
N/A

Price Target and Rating

High Price Target
$62.00
Low Price Target
$6.00
Potential Upside/Downside
+97.7%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$122.31 million
Net Margins
-2,929.30%
Pretax Margin
-2,530.46%
Return on Equity
-62.17%
Return on Assets
-54.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.68
Quick Ratio
5.68

Sales & Book Value

Annual Sales
$10.34 million
Price / Sales
52.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.05 per share
Price / Book
1.10

Miscellaneous

Outstanding Shares
53,830,000
Free Float
48,878,000
Market Cap
$537.87 million
Optionable
Optionable
Beta
-0.11
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PRTA) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners